WallStSmart

Henry Schein Inc (HSIC)vsBanco Santander SA ADR (SAN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Banco Santander SA ADR generates 255% more annual revenue ($46.84B vs $13.18B). SAN leads profitability with a 30.1% profit margin vs 3.0%. HSIC appears more attractively valued with a PEG of 1.60. SAN earns a higher WallStSmart Score of 63/100 (C+).

HSIC

Buy

56

out of 100

Grade: C

Growth: 7.3Profit: 5.5Value: 8.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.71

SAN

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 7.3Quality: 3.8
Piotroski: 4/9Altman Z: 0.38
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HSICUndervalued (+12.5%)

Margin of Safety

+12.5%

Fair Value

$93.39

Current Price

$74.25

$19.14 discount

UndervaluedFair: $93.39Overvalued
SANUndervalued (+72.4%)

Margin of Safety

+72.4%

Fair Value

$45.40

Current Price

$10.77

$34.63 discount

UndervaluedFair: $45.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.6x8/10

Reasonable price relative to book value

SAN6 strengths · Avg: 9.5/10
P/E RatioValuation
11.5x10/10

Attractively priced relative to earnings

Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Profit MarginProfitability
30.1%10/10

Keeps 30 of every $100 in revenue as profit

Operating MarginProfitability
43.7%10/10

Strong operational efficiency at 43.7%

Market CapQuality
$163.16B9/10

Large-cap with strong market position

EPS GrowthGrowth
25.3%8/10

Earnings expanding 25.3% YoY

Areas to Watch

HSIC3 concerns · Avg: 3.3/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.023/10

Elevated debt levels

SAN4 concerns · Avg: 1.8/10
PEG RatioValuation
2.532/10

Expensive relative to growth rate

Revenue GrowthGrowth
-6.4%2/10

Revenue declined 6.4%

Altman Z-ScoreHealth
0.382/10

Distress zone — elevated risk

Debt/EquityHealth
4.471/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bull Case : SAN

The strongest argument for SAN centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 30.1% and operating margin at 43.7%.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Profit Margin, Debt/Equity. Thin 3.0% margins leave little buffer for downturns.

Bear Case : SAN

The primary concerns for SAN are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 4.47 is elevated, increasing financial risk.

Key Dynamics to Monitor

HSIC profiles as a value stock while SAN is a declining play — different risk/reward profiles.

SAN carries more volatility with a beta of 0.92 — expect wider price swings.

HSIC is growing revenue faster at 7.7% — sustainability is the question.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SAN scores higher overall (63/100 vs 56/100), backed by strong 30.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Banco Santander SA ADR

FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA

Banco Santander, SA, offers various commercial and retail banking products and services to individuals, small and medium-sized companies and large companies worldwide. The company is headquartered in Madrid, Spain.

Want to dig deeper into these stocks?